Director Tamar Howson resigns; CEO Erik Lundgren appointed to board

IMMUNIC, INC.

Tamar Howson resigned from Board and Compensation Committee effective June 29, 2026, due to retirement; no disagreement.
On July 5, 2026, Board appointed CEO Erik Lundgren as Class II director until 2028 annual meeting.
Lundgren will not serve on any board committee and receives no additional compensation for director role.
Lundgren's existing employment agreement with Immunic was previously disclosed (May 27, 2026 8-K).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.